Pretreatment with statins may reduce cardiovascular morbidity and mortality after elective surgery and percutaneous coronary intervention: Clinical evidence and possible underlying mechanisms

2007 ◽  
Vol 154 (2) ◽  
pp. 391-402 ◽  
Author(s):  
Ramanna Merla ◽  
Iyad N. Daher ◽  
Yumei Ye ◽  
Barry F. Uretsky ◽  
Yochai Birnbaum
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Clinical Evidence ◽  
Elective Surgery ◽  
Coronary Intervention ◽  
Cardiovascular Morbidity ◽  
Morbidity And Mortality ◽  
Cardiovascular Morbidity And Mortality ◽  
Percutaneous Coronary ◽  
Underlying Mechanisms

Percutaneous Coronary Intervention with Concomitant Atrial Fibrillation

2018 ◽  
pp. 67-78
Author(s):  
Joseph W. Woo ◽  
Gregory K. Kim
Keyword(s):  
Atrial Fibrillation ◽  
Heart Rate ◽  
Percutaneous Coronary Intervention ◽  
Cardiac Rhythm ◽  
Elective Surgery ◽  
Coronary Intervention ◽  
Percutaneous Coronary ◽  
The Face ◽  
Ventricular Response ◽  
Response Optimization

Cardiac comorbidities are oftentimes not limited to a single diagnosis, and multiple cardiac abnormalities may have to be considered when administering an appropriate anesthetic. Atrial fibrillation is an abnormal cardiac rhythm with uncoordinated depolarization of the atria causing an irregularly irregular ventricular response. Optimization requires heart rate control as well as anticoagulation, which must be considered prior to any surgical procedure. Percutaneous coronary intervention or coronary stents are placed in the coronary arteries in the face of coronary artery stenosis. The circumstances of when the stents were placed, as well as the type of stents that were used, will determine how long dual antiplatelet therapy must be undertaken and when elective surgery can take place.

Latest Developments in Robotic Percutaneous Coronary Intervention

2021 ◽  
Author(s):  
Felix Hofmann ◽  
Oliver Dörr ◽  
Florian Blachutzik ◽  
Niklas Boeder ◽  
Albrecht Elsässer ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Large Scale ◽  
Coronary Intervention ◽  
Percutaneous Transluminal Coronary Angioplasty ◽  
Cardiovascular Morbidity And Mortality ◽  
Percutaneous Coronary ◽  
Wide Range ◽  
Procedural Success ◽  
Substantial Decline ◽  
Transluminal Coronary Angioplasty

Interventional cardiovascular medicine has seen constant progress over the last few decades. Since the first angiograms and percutaneous transluminal coronary angioplasty were carried out, this progress has been tremendous and has led to a substantial decline in cardiovascular morbidity and mortality. The purpose of this article is to report and review the latest developments and evidence in robotics-assisted percutaneous coronary intervention (rPCI) and its potential future applications, opportunities, and limitations. Contemporary evidence shows that rPCI can lead to a significant reduction in radiation exposure as well as medical hazards for cardiologists. Rates of device and procedural success remain high and there is no evidence of a disadvantage for the patient. The accuracy of implantation with a reduced geographic mismatch is a further advantage that can result in a higher quality of treatment. Even in complex coronary lesions and procedures, rPCI seems to be safe and efficient. The latest developments include telestenting over hundreds of kilometers from a remote platform. Currently, the main limitations are the absence of large-scale randomized trials for the valid assessment of the benefits and disadvantages of rPCI as well as the technical limitations of the currently available rPCI systems. rPCI is a forward-looking innovation in cardiology that is applicable to a wide range of coronary interventions. Despite the present lack of knowledge and the limited data concerning the outcome for the patient, the available literature reveals promising results that should lead to improvements for physicians and patients.

scholarly journals Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins

2011 ◽  
Vol 2011 ◽  
pp. 1-12 ◽  
Author(s):  
Enrique C. Morales-Villegas ◽  
Germano Di Sciascio ◽  
Carlo Briguori
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Cardiovascular Events ◽  
Clinical Evidence ◽  
Ldl Cholesterol ◽  
Coronary Intervention ◽  
Cholesterol Concentration ◽  
Cardiovascular Risk Reduction ◽  
Coronary Syndrome ◽  
Protective Enzyme ◽  
Percutaneous Coronary

Reduction of LDL-cholesterol concentration in serum, blocking the isoprenylation of GTPases and the activation of myocyte-protective enzyme systems are three mechanisms that currently explain the lipid and non-lipid effects of statins. However, the decrease of LDL-cholesterol, the reduction of inflammation biomarkers and even the atheroregresion, as surrogate effects to the mechanisms of action of statins would be irrelevant if not accompanied by a significant decrease in the incidence of cardiovascular events. Statins like no other pharmacological group have proven to reduce the incidence of cardiovascular events and prolong life in any clinical scenario. This article review the basic and clinical evidence that support a new indication for HMG-CoA reductase inhibitors “pharmacological myocardial preconditioning before anticipated ischemia” or hyperacute use of statins in subjects with any coronary syndrome eligible for elective, semi-urgent or primary percutaneous coronary intervention: ARMYDA-Original, NAPLES I-II, ARMYDA-ACS, ARMYDA-RECAPTURE, Non-STEMI-Korean, Korean-STEMI trials.

Sign in / Sign up

Export Citation Format

Share Document